1	Blood Eosinophil Referer	nce Values and Determinants in a Representative Adult Population					
2	Reshed Abohalaka ^a , Selin	Ercan ^a , Lauri Lehtimäki ^{b,c} , Saliha Selin Özuygur Ermis ^a , Daniil Lisik ^a ,					
3	Muwada Bashir Awad Bashir ^a , Radhika Jadhav ^a , Linda Ekerljung ^{a,d} , Göran Wennergren ^e , Jan						
4	Lötvall ^a , Teet Pullerits ^a ,	Helena Backman ^f , Madeleine Rådinger ^a , Bright I. Nwaru ^a , Hannu					
5	Kankaanranta ^{a,c,g}						
6							
7	^a Krefting Research Centr	e, Department of Internal Medicine and Clinical Nutrition, Institute					
8	of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden						
9	^b Allergy Centre, Tampere University Hospital, Tampere, Finland						
10	^c Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland						
11	^d Department of Internal Medicine/Respiratory Medicine and Allergology, Sahlgrenska						
12	Academy, University of G	othenburg, Gothenburg, Sweden					
13	^e Department of Paediatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg,						
14	Sweden						
15	^f Department of Public He	alth and Clinical Medicine, Umeå University, Umeå, Sweden					
16	^g Department of Respirate	ory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland					
17	Corresponding author:	Reshed Abohalaka					
18		Krefting Research Centre					
19		Department of Internal Medicine and Clinical Nutrition					
20		Institute of Medicine					
21		Sahlgrenska Academy					
22		University of Gothenburg, 41390 Gothenburg, Sweden					
23		Tel: +46 31 786 67 12					
24	NOTE: This preprint reports new res	eaEctWhaihasରେbech ଅଉଦାଇଥାନ kaeଙ୍କେତ୍ସାଣ୍ଟାର୍ଚ୍ଚଲେଏ should not be used to guide clinical practice.					

- 25 E-mail addresses
- 26 <u>Reshed.abohalaka@gu.se</u>
- 27 <u>selin.ercan@gu.se</u>
- 28 lauri.lehtimaki@tuni.fi
- 29 <u>selin.ozuygur@gu.se</u>
- 30 <u>daniil.lisik@gu.se</u>
- 31 <u>muwada.bashir@gu.se</u>
- 32 <u>radhika.jadhav@gu.se</u>
- 33 <u>linda.ekerljung@lungall.gu.se</u>
- 34 goran.wennergren@pediat.gu.se
- 35 jan.lotvall@gu.se
- 36 <u>teet.pullerits@lungall.gu.se</u>
- 37 <u>helena.backman@norrbotten.se</u>
- 38 madeleine.radinger@lungall.gu.se
- 39 <u>bright.nwaru@gu.se</u>
- 40 <u>hannu.kankaanranta@tuni.fi</u>
- 41 Running head: Blood Eosinophil Reference Values in general population
- 42 Abstract word count: 222/250
- 43 Total word count: 3000/3500
- 44 Tables/figures:

- 8/8
- 45 **Clinical Implications:** The upper limit of normal blood eosinophil count (BEC) in participants
- 46 free from asthma, COPD, and clinical allergy ranged between 300 and 400 cells/μL depending
- 47 on age. These results facilitate the interpretation of BEC in clinical practice.

48 Capsule summary: The upper limit of normal blood eosinophil count (BEC) in healthy
 49 individuals ranged between 300 and 400 cells/μL depending on age. Determinants of BEC
 50 values include age, smoking, obesity, asthma, and clinical allergy.

51

52 Support statement

The study was supported by the VBG Group Herman Krefting Foundation for Asthma and Allergy Research (Trollhättan, Sweden), Swedish Research Council (Stockholm, Sweden), the Swedish Heart-Lung Foundation (Stockholm, Sweden), the Swedish Asthma and Allergy Foundation (Stockholm, Sweden), Tampere Tuberculosis Foundation (Tampere, Finland), and ALF agreement (grant from the Swedish state under the agreement between the Swedish Government and the county councils, Sweden).

59

60 Conflict of interest

61 LL reports personal fees from ALK, AstraZeneca, Berlin Chemie, Boehringer-Ingelheim, Chiesi, 62 GSK, Novartis, Orion Pharma and Sanofi outside the current work. SSÖE reports conference-63 attendance related costs from Thermo Fisher Scientific outside the current work. TP reports 64 fees for lectures and/or consulting from AstraZeneca, Chiesi, GSK, Novartis and Sanofi outside 65 the current work. HB reports personal fees for lectures form AstraZeneca, Boehringer 66 Ingelheim and GSK outside the current work. NIB reports personal fees for lectures and 67 consulting from DBV Technologies and AstraZeneca outside the current work. **HK** reports fees 68 for lectures and/or consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi, Covis Pharma, 69 GSK, MedScape, MSD, Novartis, Orion Pharma and Sanofi outside the current work. The rest 70 of the authors have no conflict of interest to declare.

71

72 Abstract

Background The use of blood eosinophil count (BEC) as a prognostic biomarker in the
management of conditions such as asthma and chronic obstructive pulmonary disease (COPD)
may be complicated by factors like atopy, age, sex, smoking, and comorbidities. Therefore,
we aimed to produce reference values for BEC, considering age, asthma, COPD, and clinical
allergy for the general adult population.

78 Methods The West Sweden Asthma Study constitutes a population-representative clinical
 79 epidemiological cohort of randomly selected adults in western Sweden. From this cohort,
 80 *n*=1,145 took part in clinical examinations, including e.g. skin prick testing, specific
 81 immunoglobulin E, and BEC.

Results The upper limit (95th percentile) of BEC varied by age. It ranged between 400 to 500
cells/µL in the full sample, and from 300 to 400 cells/µL in subjects without asthma, COPD,
and clinical allergy (*n*=710). Sex, smoking, atopy, clinical allergy, obesity, asthma, COPD,
diabetes, and hypertension were statistically significantly associated with higher BEC levels.
However, only asthma and clinical allergy in the full sample, and obesity and diabetes in those
without asthma, COPD, or clinical allergy, remained statistically significant in multiple
regression analyses.

Conclusion In a population-representative sample, the upper limit of BEC in healthy adults
 ranged between 300 and 400 cells/μL, varying by age. Age, smoking, obesity, asthma, COPD,
 and clinical allergy influence BEC levels and should be considered in clinical interpretation.

92

93 Keywords: Blood eosinophil count, asthma, COPD, atopy, allergy, reference values,
94 population-representative, normal range

95

96 Abbreviations

- 97 BEC: blood eosinophil count
- 98 BMI: body mass index
- 99 COPD: chronic obstructive pulmonary disease
- 100 FEV₁: forced expiratory volume in one second
- **101** FVC: forced vital capacity
- 102 GINA: Global Initiative for Asthma
- 103 GOLD: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive
- 104 Lung Disease
- 105 ICS: inhaled corticosteroids
- 106 slgE: specific immunoglobulin E
- 107 WSAS: West Sweden Asthma Study
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- _
- 119

120 Introduction

121 Blood eosinophil count (BEC) plays a pivotal role in determining the severity, phenotypes, and 122 therapy of a spectrum of chronic inflammatory lung disorders, most notably asthma and 123 chronic obstructive pulmonary disease (COPD) [1,2]. Indeed, BEC is a valuable prognostic 124 indicator for assessing responsiveness to anti-interleukin 5 (anti-IL5) and anti-IL-4/13 125 therapies in severe asthma [3], as well as for predicting the efficacy of inhaled corticosteroids 126 (ICS) in COPD [4,5]. In addition, the Global Initiative for Asthma (GINA) recommends the use 127 of BEC to identify asthma patients with type 2 (T2) inflammation [2]. Meanwhile, the Global 128 Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 129 (GOLD) recommends the use of 300 cells/µL as a threshold of circulating eosinophils to guide 130 therapy with ICS in patients with COPD who continue to exacerbate despite appropriate 131 bronchodilator therapy [1].

132 However, the application of BEC as a biomarker in clinical practice is not straightforward. First, 133 the predictive cut-off points for BEC interpretation derived from randomized controlled trials 134 are confined to studies conducted within asthma and COPD populations [6–16]. Second, the 135 recommended BEC thresholds in clinical guidelines are subject to debate due to their 136 perceived overlap with normal eosinophil ranges [17,18]. This controversy arises from the 137 limited evidence of normal and abnormal blood eosinophil levels across diverse populations 138 with varying backgrounds and health conditions. This evidence gap is highlighted by the fact 139 that investigations into healthy populations suggest that BEC are influenced by several 140 demographic and clinical factors, including age, sex, obesity, atopy, and smoking [19–21].

Furthermore, studies having representative random samples from the general population are
 scarce. A recent systematic review by *Benson et al.* [21] that aimed to synthesize the absolute
 BEC rather than reference values, identified 14 studies conducted in the general population.

Only one of these studies used a random sample directly from the population itself [22].
Conversely, two additional studies, while encompassing a considerable sample size, did not
recruit participants from the general population [20] nor did report reference values for the
healthy cohort [23]. Thus, the typical range of BEC in the general population is not wellestablished. Therefore, our objective was to determine the BEC reference values and its
determinants in a population-representative sample.

- 150
- 151 Methods

152 Study area and population

153 The West Sweden Asthma Study (WSAS) has been described in detail previously [24]. Briefly, 154 WSAS examines individuals aged 16 to 75 years at recruitment, randomly selected from the 155 general population of western Sweden. Commencing in 2008, a total of 30,000 subjects within 156 the specified age range were randomly selected through the Swedish Population Register and 157 invited to take part in a postal survey. Of those invited, 18,087 individuals participated in the 158 survey study. Subsequently, a random subset of 2,000 individuals were invited to 159 comprehensive clinical examinations, of which 1,145 participated (Figure 1). All participants 160 signed informed consent, and the study was approved by the regional ethics board in 161 Gothenburg, Sweden.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.10.24315149; this version posted October 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in





163

Figure 1 Flow chart of participation in the study. Clinical allergy was defined by the presence of allergic sensitization coupled with consistent self-reported allergic symptoms attributable to the same allergen. COPD: Chronic Obstructive Pulmonary Disease.

168 **Clinical examinations**

- 169 The examinations included, but not limited to, blood cell quantification, skin prick testing 170 (SPT), specific immunoglobulin E (sIgE) level assessment, and measurement of height and
- 171 weight. Additionally, the clinical examination encompassed in-depth, structured interviews
- 172 and administration of questionnaires pertaining to respiratory diseases and symptoms,
- 173 morbidities, healthcare utilization, and potential risk factors.
- 174

175 Assessment of sensitization and blood eosinophils

176 Sensitization was evaluated through the determination of sIgE levels and SPT for 11

177 aeroallergens (Details are provided in the supplementary file). BECs were determined using

- standard procedures at Sahlgrenska University Hospital (Gothenburg, Sweden) with ADVIA[®]
 2120i Hematology System (Siemens Healthineers, Erlangen, Germany), and are reported as
 the number of cells per microliter (μL).
- 181

182 Definitions of diseases

183 Clinical allergy was defined as the presence of allergic sensitization, indicated by either a 184 positive SPT or elevated sIgE level to at least one allergen (atopy), coupled with self-reported 185 allergic symptoms attributable to the same allergen. The presence of metabolic disorder was 186 confirmed by obesity (body mass index [BMI] ≥30 kg/m²) or any of the following self-reported 187 conditions: hypertension, hyperlipidaemia, or diabetes [25]. Detailed definition of Asthma 188 and COPD are provided in the supplementary file.

189

190 Statistical analyses

191 In the establishment of reference values, the presumption is that the spectrum of values 192 derived from a cohort of healthy individuals is a proxy for normal values. Consequently, 193 individuals manifesting values beyond the norm, typically delineated by the central 90% of 194 the range of values in the healthy population (upper limit of normal or 95th percentile and 195 lower limit of normal or 5th percentile), are frequently characterized as exhibiting anomalous 196 outcomes [26, 27]. As a result, our reporting considers the 95th percentile of BEC as the upper 197 limit of normal. Due to the non-normal distribution of BEC values exhibiting a right-skewed 198 shape, percentiles were derived from the logarithmically transformed dataset, as previously 199 described [20]. Statistical comparisons were carried out using independent Student's t-tests. 200 Statistical significance was deemed present at a threshold of p<0.05.

201 A multiple binary logistic regression model was applied to compute odds ratios (OR) 202 accompanied by 95% confidence intervals (CI) for the purpose of elucidating associations 203 between various factors and BEC values higher than the upper limit (95th percentile), adjusting 204 for potential confounding variables. All statistical analyses were executed utilizing SPSS 29.0 205 (IBM Corp, New York, USA). 206 207 Results 208 Characteristics of the random sample 209 The random sample comprised of 1,145 individuals, with 46.8% being males. The mean age 210 of the total study sample was 50.4±15.4 years (mean±standard deviation (SD)). Nearly half of 211 the participants (50.8%, n=582) reported no history of smoking, while 11.4% were current 212 smokers. Of the participants, 37.8% (n=426) were sensitized (atopic), while 29.8% (n=337) 213 met the criteria for clinical allergy (Table 1). Individuals with clinical allergy were younger 214 (45.6±14.7 years), had more males, and more non-smokers than those without clinical allergy 215 (Table 1). For other characteristics of those with asthma with or without clinical allergy, see 216 Table S1.

- 217
- 218

219 Blood-eosinophil count in the random sample

In the full random sample, the upper limit of BEC was 400 cells/μL across all ages, except for
those aged 50-60 years, where it reached nearly 500 cells/μL (Figure 2A). To assess the
influence of asthma and COPD on BEC, we excluded patients with these conditions (Figure
223 2B). The 95th percentile BEC remained stable at 400 cells/μL for those without asthma and
non-COPD individuals across different ages, except for those aged 30-40 years, where it was

around 300 cells/µL. Next, we examined the impact of clinical allergy on BEC (Figure 2C). Among participants without clinical allergy, asthma, or COPD (n=710), the upper BEC limit increased with age from 300 cells/µL for those aged <40 years to 400 cells/µL for subjects aged >40 years (Table 2). Further, excluding atopic subjects, there was a minimal change in the 95th percentile compared to those without clinical allergy (Figure 2D). Detailed reference values of those subjects (n=628) are presented in Table S2.

- The 75th percentile of BEC was similar to the 95th percentile in the entire random sample (Figure 2A). However, when excluding those with asthma, COPD, clinical allergy, or atopy, the 75th percentile remained constant at 200 cells/ μ L across all age groups (Figure 2B-2D). Meanwhile, the median BEC in the full random sample increased gradually with age, from 100 cells/ μ L to a peak of 200 cells/ μ L for those aged >30 years, with similar trends in the other groups (Figure 2).
- 237

238 The impact of asthma, COPD, and clinical allergy on BEC

To understand the rise in the upper limit of normal and the 75th percentile of BEC in people
aged 50-60 years in the random sample, we focused on the 95th and 75th percentiles of BEC
in subjects with asthma, COPD, or clinical allergy. Detailed analyses of eosinophil and BEC
values for the subgroups with asthma and clinical allergy in the random sample are illustrated
in Figures S1A- C.





Figure 2: The characteristics of blood eosinophil count across different age groups, delineated for (A) the entire population-representative random sample comprising of 1,145 individuals, (B) random sample participants excluding asthma and COPD patients (n = 948), (C) individuals additionally devoid of clinical allergy (n = 710), and (D) individuals additionally devoid of atopy (n = 628). The depicted blue region demarcates the space between the median and 75th percentile curves, while the red region signifies the interval between the 75th percentile and 95th percentile curves.

Determinants of BEC

A comprehensive understanding of the determinants affecting the upper normal limit of BEC within the general population necessitates a comparative investigation of BEC upper 95th percentile values across diverse demographic and clinical parameters. However, the 95th percentile is a collective outcome and not individually available for each patient. Hence, to comprehend the determinants influencing BEC in the general population, we evaluated the effect of various factors, previously reported to affect BEC, on mean BEC levels in our full random sample (Table 3). BEC levels were significantly higher in men compared to women and in ever-smokers compared to never-smokers. BEC was significantly higher in those with than in those without clinical allergy, in those with than in those without atopy, and in those with than those without asthma. Moreover, high BEC was significantly linked to the presence 265 of COPD, obesity, hypertension, and a minimum of one metabolic disease (Table 3).

267 Multiple linear regression model for factors associated with higher BEC values

268 Multiple linear regression analyses were conducted to discern factors associated with higher 269 BEC values considering potential confounders. To achieve this objective, two distinct analyses 270 were performed: one including the entire random sample and another focusing solely on 271 participants lacking any predisposing factors to eosinophilic inflammation, such as allergies, 272 atopy, asthma, or COPD. The initial analysis revealed that only asthma and clinical allergy – 273 not atopy- were significant determinants of BEC in the whole sample (Table 4A). 274 Subsequently, to discern factors linked to higher BEC in the absence of established morbidities 275 known to increase BEC, such as atopy, clinical allergy, asthma, and COPD, we conducted a 276 separate analysis within this subset, in which diabetes and obesity were identified as 277 significant predictors of BEC (Table 4B).

Binary logistic regression model for factors associated with elevated BEC values:

278 279 280 281 282 To evaluate factors associated with BEC above the upper limit of normal (>400 cells/ μ l), we 283 conducted adjusted binary logistic regression analyses similar to the above linear regressions. 284 In the whole sample, asthma and ever smoking were significantly associated with high BEC 285 (Figure 3). Diabetes, hypertension and ever smoking were significantly associated with high 286 BEC in participants without atopy, asthma or COPD (Figure 3).



294 295 296 297 298 299 300 301 302

Figure 3 Adjusted binary logistic regression analyses (OR and 95% CI) for BEC > 400 cells/uL in the full populationrepresentative random sample (n = 1145; red), and in subjects without clinical allergy, atopy, asthma, or COPD (n = 628; blue). Bold font indicates significant OR (p < 0.05) associations. COPD: chronic obstructive lung disease.

Discussion

In our population-representative random sample, the upper limit of BEC ranged from 400 to 500 cells/ μ L, depending on age. In individuals without asthma, COPD, or clinical allergy, the upper limit of BEC increased from 300 to 400 cells/ μ L after the age of 40. Sex, smoking, atopy, clinical allergy, obesity, asthma, COPD, diabetes, and hypertension were significantly associated with higher BEC levels. However, only asthma and clinical allergy in the full sample, and obesity and diabetes in healthy individuals, remained significant determinants of BEC. Asthma and ever smoking were associated with high BEC in all subjects, while diabetes, hypertension, and ever smoking were associated with high BEC in healthy participants. These

findings clarify the highly needed typical BEC range in the general population, a crucialbiomarker for diagnosing, treating, and managing asthma and COPD [1,2].

305 Several studies have attempted to establish reference values for BEC in their populations [20, 306 28–32]. The upper limit of normal BEC ranged from 550 to 630 cells/ μ L in a French population 307 [29], from 500 to 600 cells/µL in a Moroccan population [31], and from 450 to 590 cells/µL in 308 a Turkish population [28], depending on sex and age. In healthy individuals, the upper limit 309 ranged from 500 to 800 cells/ μ L in a Thai population [30], and from 490 to 640 cells/ μ L in a 310 Kenyan population [32], depending on sex. Even though the upper limit of normal BEC in our 311 study similarly varied by age with relatively lower range, it is important to note that most of 312 these studies do not represent the general population accurately, and their outcomes could 313 be affected. They either analysed data from selected registries or small sample sizes instead 314 of the large randomly selected sample from the general population. In addition, the studies 315 using healthy populations have employed impractical strict criteria in defining their healthy 316 population such as excluding obese, smokers, alcohol consumers, or participants with any 317 comorbidities. In particular, our findings align more closely with those of Hartl et al. [20], who 318 reported a 95th percentile BEC range of 360 to 450 cells/µL in the general population and 290 319 to 350 cells/ μ L in healthy individuals, using a large sample size.

The reference intervals for BEC utilized in diverse contexts exhibit variability, encompassing upper limits ranging from the 75th to-the 90th, the 95th, and as high as the 97.5th percentile [20,28–34]. Hartl et al. [20] designated the 75th percentile as a threshold denoting "high blood eosinophils", employing it in their forced-entry binary multivariable logistic regression analysis. However, our analysis reveals that the sensitivity of the 75th percentile to alterations is somewhat diminished, contingent upon factors such as age, atopy, clinical allergy, and smoking. Conversely, the 95th percentile exhibited greater sensitivity to changes in these

factors. In addition, using the 75th percentile to label something as "high" implies that 25% of
healthy adults are abnormal, which is not reasonable. Even those above the 95th percentile
do not necessarily have a disease. However, their significant deviation from the norm suggests
a higher likelihood of clinically relevant abnormality. Consequently, we employed the 95th
percentile as the basis for our adjusted binary logistic regression analysis.

332 The median of BEC as reported in both healthy and general population studies exhibits a range 333 spanning (100-200) cells/ μ L [8,13,14,23,35], with a proclivity to approximate 200 cells/ μ L in 334 investigations with large sample sizes [8,21, 23]. Consistent with existing literature, our study 335 observed a distribution of random sample BEC medians ranging from 100 cells/ μ L in the age 336 group under 30 years to 200 cells/ μ L in the older age strata. Moreover, in concordance with 337 asthma population studies, the median BEC has been reported to fluctuate between 157 and 338 298 cells/µL [6,7,15,16,21,36,37], demonstrating a tendency to approximate 200 cells/µL in 339 studies involving a sizable participant pool [6,7,15,21]. In our study, the median BEC varied 340 from 180 cells/ μ L among asthmatic participants under 30 years of age to 200 cells/ μ L in the 341 remaining age strata. Although the absolute and average BEC values are parallel to those in 342 other cohorts, our study uniquely helps determine the abnormality of a person's measured 343 value by providing reference values from a representative sample of the general population. 344 In our study, when comparing BEC levels between groups, we found that male sex, smoking 345 (both current and past), atopy, clinical allergy, obesity, asthma, COPD, diabetes, and 346 hypertension were significantly associated with higher BEC levels. Previous studies have 347 reported similar findings regarding male sex [20,21,23,28,34], current smoking [20,34], ever 348 smoking [34], metabolic disorders [20,23,28], and allergy parameters [20,23,34]. However, 349 our study is the first to characterize the determinants of BEC levels using multivariate linear 350 regression, showing that asthma and clinical allergy are significant predictors in the full

351 random sample, while obesity and diabetes are significantly associated in healthy individuals. 352 Giovannelli et al. [23] also identified allergic asthma, atopy, and BMI as predictors of BEC in 353 their cohort, although BMI was only significant among non-smokers. However, there was no 354 analysis for predictors in healthy subgroup in their study. Additionally, no prior study has 355 explored the impact of clinical allergy on BEC within the general population; most studies 356 have evaluated the influence of atopy. This is of particular significance given that clinical 357 allergy retains its status as a substantive predictor of BEC even after adjustments for several 358 confounders including atopy in our multiple linear regression analysis. Moreover, clinical 359 allergy, rather than atopy alone, is used to define T2 inflammation in asthma guidelines [2].

360 The WSAS cohort presents several notable strengths. Firstly, the study encompasses a sizable 361 sample, systematically selected without any exclusion criteria, rendering it representative of 362 the adult population in Western Sweden. Secondly, our investigation marks the first 363 exploration of the impact of clinical allergy, in conjunction with atopy, among the participants. 364 Challenges often arise in diagnosing factors like clinical allergy and asthma, with many studies 365 relying on self-reported disease. In contrast, our study employed a meticulous classification 366 process, involving thorough clinical examinations overseen by pulmonary and allergy 367 specialists. This approach enhances the reliability of our findings, which reveal that while 368 asthma and clinical allergy are predictors of BEC in the general population, only asthma and 369 a history of smoking are linked to BEC levels above the upper normal limit. The fact that 370 allergic parameters do not pose a risk for abnormal BEC values underscores the potential 371 utility of our established upper limit of normal for interpreting BEC values in asthma clinics. 372 Nevertheless, it is crucial to note the limitation of the present study to adults, acknowledging 373 that the predicted BEC values might be substantially different among children and

adolescents. Additionally, our study does not account for less common infectious or chronic
diseases that could potentially be linked to elevated BEC.

376 The upper limit of normal BEC in participants without asthma, COPD, and clinical allergy 377 ranged between (300-400) cells/µL depending on age. GINA recommends the use of BEC to 378 identify asthma patients with T2 inflammation using cutoff points such as 150 and 300 cells/µL 379 [2]. Similarly, GOLD recommends the use of 300 cells/µL as a threshold of BEC to guide 380 therapy with ICS in COPD patients [1]. It is important to note that these cutoff points fall within 381 the normal BEC range for healthy adults in our cohort, indicating that while they are useful 382 for predicting treatment response, they are not necessarily considered "high". However, the 383 observation that only asthma and smoking, but not clinical allergy, are associated with 384 abnormal BEC values highlights the potential for establishing treatment response indicators 385 for asthma and COPD that align with reference values for healthy individuals.

386 In conclusion, the 95th percentile in BEC ranged depending on age between (400- 500) 387 cells/µL in a random sample of the general adult population, and between (300-400) cells/µL 388 in individuals free from asthma, COPD, and clinical allergy. Additionally, asthma and smoking, 389 though not allergic parameters, were identified as risk factors for having BEC above the upper 390 limit of normal in the full sample. In subjects without asthma, clinical allergy, or COPD, 391 smoking, diabetes, and hypertension were recognized as risk factors for elevated BEC. 392 Consequently, these factors merit careful consideration during the clinical interpretation of 393 BEC.

- 394
- 395
- 396
- 397

398 Authors	' contributions
-------------	-----------------

- 399 Conception and design RA, SE, LL, BIN, HK,
- 400 ; Data analysis RA, SE, HB, BIN, HK,
- 401 ; Data collection RA, SE, RJ, DL, SÖ, MB, LE, MR, JL, GW, TP, BIN, HK,
- 402 ; Manuscript writing RA, BIN, HK
- 403 ; Manuscript review and editing all authors.

-

- .._

-

Λ	C	C
4	۷	۷

Table 1. Characteristics of study subjects with or without asthma or clinical allergy (N=1,145).

	Without Asthma	With Asthma	Without Clinical allergy	With Clinical allergy
Subjects n (%)	964 (84.2)	181 (15.8)	792 (70.2)	337 (29.8)
Asthma n (%)	-	181 (100)	65 (8.2)	115 (34.1)
Clinical allergy [*] n (%)	222 (23.4)	115 (63.9)	-	337 (100)
Demographics				
Age (v) mean (SD)	50 7 (15 5)	48 7 (15 1)	52 1 (15 3)	45 6 (14 7)
Male sex n $(\%)$	456 (47 3)	80 (44 2)	349 (44 1)	179 (53 1)
BML kg/m ² mean (SD)	26.0 (4.1)	269(45)	26 1 (4 1)	26 2 (4 3)
Education years over 12 years n (%)	437 (45.4)	90 (50.0)	345 (43.6)	175 (52.9)
Never smokers n (%)	496 (51.5)	86 (47.5)	380 (48.0)	196 (58.2)
Current smokers n (%)	103 (10.7)	27 (14.9)	99 (12.5)	29 (8.6)
Pack-vear mean (SD)	14.0 (12.8)	17.5 (15.9)	14.8 (13.1)	13.3 (14.0)
	()		(,	
Allergic symptoms				
Age at onset of symptoms mean (SD)	24.5 (16.8)	17.8 (15.0)	28.6 (18.1)	18.6 (14.3)
Eyes and nasal symptoms n (%)	249 (49.2)	106 (68.8)	119 (33.1)	234 (79.9)
Ever allergic nasal symptoms n (%)	301 (31.3)	129 (71.3)	152 (19.3)	273 (81.0)
Current allergic nasal symptoms n	454 (88.0)	147 (94.8)	309 (84.5)	285 (96.0)
(%)				
Atopy and allergy				
>1 nositive reaction in SPT [#] n (%)	223 (34 0)	102 (72 9)	60 (11 7)	265 (94.0)
≥ 1 positive sign n (%)	223 (34.0)	111 (63 /)	65 (8 5)	203 (34.0)
21 positive sign in (%)	201 (27.4)	122 (67.9)	03(0.5)	227 (31.7)
Clinical allorgy to mito n (%)	304 (32.1) 42 (4 4)	122 (07.0)	92 (11.0)	237 (100) 24 (24 Q)
Clinical allergy to furry animals n (%)	42 (4.4) 74 (7.8)	42 (23.3) 71 (20 <i>1</i>)	-	04 (24.9) 145 (42.0)
Clinical allergy to fully animals if (%)	168 (17 7)	71 (39.4) 07 (52 0)	_	265 (78 6)
Clinical allergy to puts n (%)	108(17.7)	97 (33.9) 40 (28 0)	-	203 (78.0)
Clinical allergy to seafood or dairy n	40 (4.4) 38 (7 1)	49 (20.0)	-	69 (27.5) 57 (17.6)
(%)	56 (4.1)	15 (10.5)		57 (17.0)
(/0)				
	22 (2.2)	17 (0 4)	26 (2 2)	10 (2 0)
CUPD	22 (2.3) 122 (12 7)	17 (9.4) 40 (22 1)	20 (3.3) 112 (14 2)	IU (3.U)
Diabatas mallitus	132 (13.7) 27 (2.9)	40 (ZZ.I) 0 (E 0)	113 (14.3) 27 /2 4)	33 (10.3) 19 (E 4)
Hypertension	37 (3.8) 375 (72 E)	5 (3.0) 18 (26 7)	27 (3.4) 107 (25 0)	10 (3.4) 67 (20 1)
Other cardiovascular diseases	223 (23.3) 112 (11 7)	40 (20.7) 22 (12 7)	197 (23.0) 08 (12 <i>1</i>)	27 (0 5)
Hyperlinidaemia	151 (15 7)	23 (12.7) 27 (17.7)	30 (12.4) 120 (16 2)	32 (3.3) 17 (12 0)
Metabolic disease	131 (13.7) 277 (20.1)	32 (17.7) 83 (15 9)	129 (10.3) 321 (AO 5)	47 (13.9) 127 (27 7)
Gastroesonhageal reflux disease	۲ <u>۱۵۵ (۱۵ ۲)</u> ۱۳۵	102 (4 3. <i>3)</i>	342 (40.3)	163 (18 1)
Jash Jesuphagean Lellux disease	+09 (42.3)	102 (30.4)	JHZ (HJ.J)	103 (40.4)

429

Data was presented as n (%) or mean (SD). BMI= body mass index, SPT = skin prick test, sIgE = specific immunoglobulin E, COPD = chronic obstructive pulmonary disease. * Some participants (N = 16) did not undergo SPT test nor sIgE, so they have been excluded from the total count of clinical allergy. #Some participants (N = 349) did not undergo SPT test, so they have been excluded from the total percentage.

431 Table 2. The descriptive values of BEC in non-allergic, non-asthmatic and COPD-free randomly selected participants (n = 710)

A = -		N /	CD	DE	DOF	DEO	DZE	DOF
Age	n	iviean	SD	P5	P25	P50	P75	P95
(years)		cells/uL	cells/uL	cells/µL	cells/µL	cells/uL	cells/uL	cells/uL
18-30	81	153	95	50	90	100	200	300
30-40	95	154	107	28	80	120	200	300
40-50	139	169	112	40	100	130	200	400
50-60	140	178	100	61	100	200	200	400
>60	255	175	109	60	100	200	200	400



Table 3. The blood eosinophil counts in the full random sample according to the demographic features and absence or presence of different conditions (N=1,145).

Eosinophils Mean (SD)					
Condition	Condition	Condition	<i>p</i> value		
	Absent	Present			
Demographics					
Male sex	181 (122)	195 (124)	0.026		
Ever smoker	178 (115)	196 (130)	0.007		
Current smoker	185 (122)	205 (126)	0.040		
Allergic Symptoms					
Eye and nasal symptoms	189 (128)	204 (132)	0.072		
Ever allergic nasal symptoms	175 (115)	206 (133)	<0.001		
Current allergic nasal symptoms	174 (111)	200 (132)	0.056		
Current usage of antihistamines	195 (155)	216 (138)	0.130		
Atopy and Allergy					
≥1 positive reaction in SPT [#]	170 (111)	210 (133)	<0.001		
≥1 positive sIgE	176 (115)	213 (136)	<0.001		
Atopic (SPT or slgE)	174 (113)	210 (134)	<0.001		
Clinically allergic to mite	185 (120)	217 (149)	0.011		
Clinically allergic to furry animals	182 (118)	222 (148)	<0.001		
Clinically allergic to pollen	179 (119)	214 (130)	<0.001		
Clinically allergic to nuts	185 (121)	225 (145)	0.001		
Clinically allergic to seafood or dairy	185 (121)	244 (157)	<0.001		
Having at least one clinical allergy	174 (113)	218 (137)	<0.001		
Morbidities					
Obesity	184 (123)	208 (123)	0.009		
Asthma	179 (115)	232 (151)	<0.001		
COPD	185 (120)	238 (186)	0.004		
Diabetes mellitus	186 (122)	220 (148)	0.031		
Hypertension	184 (122)	198 (126)	0.044		
Other cardiovascular diseases	185 (121)	202 (135)	0.063		
Hyperlipidaemia	186 (121)	196 (132)	0.143		
Metabolic disease	182 (120)	196 (127)	0.030		
Gastroesophageal reflux disease	187 (118)	187 (127)	0.487		

Data is presented as mean (SD). SPT = skin prick test, sIgE = specific immunoglobulin E, COPD = chronic obstructive pulmonary disease. #Some participants (n = 349) did not undergo SPT test, so they have been excluded from this analysis. Statistical significances were evaluated by independent samples t-test. P < 0.05 is considered significant.

Table 4: Determinants of blood eosinophil count values in adjusted multiple linear regression analysis of population-representative full random sample (N=1,145) (A) and in participants free from asthma, COPD, clinical allergy, and atopy (n=628) (B)

chilical allergy, and alopy (11–020) (B).					
	Coefficient B	Std. Error	Lower 95% Cl	Upper 95% Cl	P value
A Full random sample					
Demographics					
Age (years)					
> 60	4.81	8.87	-12.59	22.21	0.588
< 30	-15.97	11.42	-38.37	6.44	0.162
Male sex	8.18	7.45	-6.43	22.79	0.272
BMI (kg/m ²)					
Underweight (BMI < 18.5)	-58.29	38.62	-134.07	17.48	0.131
Overweight (25 ≤BMI < 30)	4.504	8.30	-11.78	20.79	0.588
Obese (BMI ≥ 30)	22.230	13.85	-4.95	49.41	0.109
Ever smoking	12.308	8.05	-3.49	28.11	0.127
Currently smoking	13.988	12.39	-10.31	38.29	0.259
, 3					
Morbidities					
Asthma	34.09	10.55	13.39	54.79	0.001
COPD	24.60	21.17	-16.95	66.14	0.246
Hypertension	12.93	12.62	-11.83	37.69	0.306
Diabetes	23.14	19.12	-14.38	60.66	0.226
Metabolic disease (≥1)	-11.77	13.13	-37.53	14.00	0.370
Atopy	7.60	13.31	-18.51	33.71	0.568
Clinical allergy [#]	29.98	14.24	2.04	57.93	0.035
B Participants free from asthma.					
COPD. and clinical allergy					
Demographics					
Age (vears)					
> 60	2.93	9.60	-15.92	21.78	0.760
< 30	-0.60	14.24	-28.57	27.37	0.966
Male sex	3 32	8 56	-13 49	20.14	0.698
$BMI (kg/m^2)$	0.02	0.00	10.10	20121	0.050
Underweight (BMI < 18 5)	-48 95	37 15	-121 91	24 01	0 188
Overweight (25 \leq BMI \leq 30)	9 120	9 71	-9.95	28.19	0 348
Obese ($BMI > 30$)	39 59	15 77	8.62	70 55	0.012
Ever smoking	12.46	9.03	-5.28	30.21	0.168
Currently smoking	8 87	14 46	-19 58	37.22	0.100
currently shloking	0.02	14.40	13.30	57.22	0.342
Morbidities					
Hypertension	20.12	14.25	-7.85	48.10	0.158
Diabetes mellitus	60.05	24.09	12.74	107.37	0.013
Metabolic disease (≥1)	-22.22	15.02	-51.71	7.27	0.139

482 483 484

Variables linked with the elevation of Blood Eosinophil Count (BEC) were examined through multiple linear regression analyses including all the variables presented in the table. Data are presented as the unstandardized b coefficient, standard error of b, and 95% CI. BMI= body mass index, COPD = chronic obstructive pulmonary disease.

References:

- 1 GOLD GI for COLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [Internet]. 2023Report No.: 2023. Available from: https://goldcopd.org/2023-gold-report-2/.
- 2 GINA GI for A. Global Strategy for Asthma Management and Prevention [Internet]. 2023Report No.: 2023. Available from: https://ginasthma.org/wpcontent/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf.
- 3 Ortega HG, Liu MC, Pavord ID, *et al.* Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. *N Engl J Med* 2014; 371: 1198–1207.
- 4 Siddiqui SH, Guasconi A, Vestbo J, *et al.* Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2015; 192: 523–525.
- 5 Pavord ID, Lettis S, Locantore N, *et al.* Blood eosinophils and inhaled corticosteroid/longacting β-2 agonist efficacy in COPD. *Thorax* 2016; 71: 118–125.
 - 6 Price DB, Rigazio A, Campbell JD, *et al.* Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. *Lancet Respir Med* 2015; 3: 849–858.
 - 7 Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy 2016; 9: 1–12.
 - 8 Vedel-Krogh S, Fallgaard Nielsen S, Lange P, *et al.* Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. *Clin Chem* 2017; 63: 823–832.
 - 9 Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med United States; 2011; 184: 1125–1132.
 - 10Pavord ID, Korn S, Howarth P, *et al.* Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet Lond Engl* 2012; 380: 651–659.
 - 11 Calverley PMA, Tetzlaff K, Vogelmeier C, *et al.* Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2017; 196: 1219–1221.
 - 12 Watz H, Tetzlaff K, Wouters EFM, *et al.* Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet Respir Med* 2016; 4: 390–398.
 - 13 Racine G, Castano R, Cartier A, *et al.* Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma. *J Allergy Clin Immunol Pract* 2017; 5: 1371-1377.e1.

14Bouzigon E, Monier F, Boussaha M, *et al.* Associations between Nitric Oxide Synthase Genes and Exhaled NO-Related Phenotypes according to Asthma Status. *PLOS ONE* Public Library of Science; 2012; 7: e36672.

1 2 3

6 7 8

9 10 11

19

20 21

22 23

24 25 26

27 28 29

34 35

- 4 15Tuomisto LE, Ilmarinen P, Niemelä O, *et al.* A 12-year prognosis of adult-onset asthma:
 Seinäjoki Adult Asthma Study. *Respir Med* 2016; 117: 223–229.
 - 16Kerkhof M, Tran TN, Soriano JB, *et al.* Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. *Thorax* 2018; 73: 116– 124.
 - 17 Bafadhel M, McKenna S, Terry S, *et al.* Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. *Am J Respir Crit Care Med* 2012; 186: 48–55.
- 12 18Criner GJ, Celli BR, Brightling CE, *et al.* Benralizumab for the Prevention of COPD Exacerbations. *N Engl J Med* 2019; 381: 1023–1034.

14
 19 Higuchi T, Omata F, Tsuchihashi K, *et al.* Current cigarette smoking is a reversible cause of elevated white blood cell count: Cross-sectional and longitudinal studies. *Prev Med Rep* 2016; 4: 417–422.

- 17 20 Hartl S, Breyer M-K, Burghuber OC, *et al.* Blood eosinophil count in the general population: typical values and potential confounders. *Eur Respir J* 2020; 55: 1901874.
 - 21 Benson VS, Hartl S, Barnes N, *et al.* Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. *Eur Respir J* 2022; 59: 2004590.
 - 22 Musk AW, Knuiman M, Hunter M, *et al.* Patterns of airway disease and the clinical diagnosis of asthma in the Busselton population. *Eur Respir J* 2011; 38: 1053–1059.
 - 23 Vedel-Krogh S, Nielsen SF, Lange P, *et al.* Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. *Am J Respir Crit Care Med* American Thoracic Society - AJRCCM; 2016; 193: 965–974.
 - 24Nwaru BI, Ekerljung L, Rådinger M, *et al.* Cohort profile: the West Sweden Asthma Study (WSAS): a multidisciplinary population-based longitudinal study of asthma, allergy and respiratory conditions in adults. *BMJ Open* 2019; 9: e027808.
 - 25Zakir F, Mohapatra S, Farooq U, *et al.* Chapter 1 Introduction to metabolic disorders. In: Dureja H, Murthy SN, Wich PR, et al., eds. *Drug Deliv Syst Metab Disord* [Internet] Academic Press; 2022 [cited 2024 Jul 17]. p. 1–20. Available from: https://www.sciencedirect.com/science/article/pii/B9780323996167000013.
 - 26Tuomisto LE, Ilmarinen P, Lehtimäki L, *et al.* Immediate bronchodilator response in FEV1 as a diagnostic criterion for adult asthma. *Eur Respir J* 2019; 53: 1800904.
- 36
 27S. Stanojevic, A. Wade, J. Stocks. Reference values for lung function: past, present and future. *Eur Respir J* 2010; 36: 12.

- 28Ozarda Y, Ichihara K, Bakan E, *et al.* A nationwide multicentre study in Turkey for establishing reference intervals of haematological parameters with novel use of a panel of whole blood. *Biochem Medica* 2017; 27: 350–377.
- 29 Troussard X, Vol S, Cornet E, *et al.* Full blood count normal reference values for adults in France. *J Clin Pathol* 2014; 67: 341–344.
- 30Wongkrajang P, Chinswangwatanakul W, Mokkhamakkun C, *et al.* Establishment of new complete blood count reference values for healthy Thai adults. *Int J Lab Hematol* 2018; 40: 478–483.
- 31 Bakrim S, Motiaa Y, Benajiba M, *et al.* Establishment of the hematology reference intervals in a healthy population of adults in the Northwest of Morocco (Tangier-Tetouan region). *Pan Afr Med J* Uganda; 2018; 29: 169.
- 32Omuse G, Maina D, Mwangi J, *et al.* Complete blood count reference intervals from a healthy adult urban population in Kenya. Nagler M, ed. *PLOS ONE* 2018; 13: e0198444.
- 33 Karita E, Ketter N, Price MA, *et al.* CLSI-Derived Hematology and Biochemistry Reference
 Intervals for Healthy Adults in Eastern and Southern Africa. Wang C, ed. *PLoS ONE* 2009;
 4: e4401.
 - 34Giovannelli J, Chérot-Kornobis N, Hulo S, *et al.* Both exhaled nitric oxide and blood eosinophil count were associated with mild allergic asthma only in non-smokers. *Clin Exp Allergy J Br Soc Allergy Clin Immunol* 2016; 46: 543–554.
 - 35 Malinovschi A, Fonseca JA, Jacinto T, *et al.* Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. *J Allergy Clin Immunol* 2013; 132: 821-827.e1-5.
 - 36 Agarwal R, Aggarwal AN, Garg M, *et al.* Cut-off values of serum IgE (total and A. fumigatus -specific) and eosinophil count in differentiating allergic bronchopulmonary aspergillosis from asthma. *Mycoses* 2014; 57: 659–663.
 - 37Tran TN, Khatry DB, Ke X, *et al.* High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. *Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol* 2014; 113: 19–24.